Details for Patent: 12,310,978
Which drugs does patent 12,310,978 protect, and when does it expire?
Patent 12,310,978 protects TLANDO and is included in one NDA.
This patent has one patent family member in one country.
Summary for Patent: 12,310,978
| Title: | Composition and method for oral delivery of androgen prodrugs |
| Abstract: | Provided oral testosterone undecanoate compositions can be administered to hypogonadal males with a meal without the fat content of the meal substantially effecting bioavailability. |
| Inventor(s): | Mahesh V. Patel, Nachiappan Chidambaram, Satish K. Nachaegari |
| Assignee: | Lipocine Inc |
| Application Number: | US16/726,572 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 12,310,978
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verity | TLANDO | testosterone undecanoate | CAPSULE;ORAL | 208088-001 | Mar 28, 2022 | RX | Yes | Yes | 12,310,978 | ⤷ Start Trial | METHODS OF RESTORING TESTOSTERONE CONCENTRATION FOR CONDITIONS ASSOCIATED WITH DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE IN A MALE SUBJECT | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,310,978
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2016205423 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
